<DOC>
	<DOCNO>NCT00005100</DOCNO>
	<brief_summary>OBJECTIVES : I . Compare growth hormone ( GH ) level baseline glucose suppression measure polyclonal radioimmunoassay highly sensitive immunoradiometric assay ( IRMA ) patient acromegaly normal volunteer . II . Measure level IGF-I binding protein , IGFBP-3 , cohort . III . Determine correlation level IGF-I IGFBP-3 GH suppressibility assess sensitive IRMA . IV . Determine patient demonstrate biochemical feature mild GH excess risk progression active disease .</brief_summary>
	<brief_title>Measurement Outcome Surgical Treatment Patients With Acromegaly</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Blood sample collect assessed growth hormone IGF-I polyclonal radioimmunoassay ( RIA ) immunoradiometric assay ( IRMA ) . Growth hormone measure baseline 60 , 90 , 120 minute 100 g glucose drink . Serum glucose measure baseline 2 hour post dextrose administration glucose hexokinase method . Clinical score determine headache , perspiration , fatigue , joint pain , acne . Exams test may repeat every 6 month 2 year .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis acromegaly treat transsphenoidal surgery Biochemically histologically confirm growth hormone secrete tumor OR Healthy volunteer Prior/Concurrent Therapy Surgery : See Disease Characteristics Greater 6 month since prior surgery Other : At least 1 month since prior bromocriptine octreotide Patient Characteristics Performance status : Ambulatory Hepatic : No active hepatic disease Renal : No active renal disease Other : No diabetes mellitus No glucose intolerance Hypopituitarism allow stable dos replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>acromegaly</keyword>
	<keyword>endocrine disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>